How does BLNE's Q3 performance compare to past quarters?

**Bloomfield Technologies (BLNE) experienced a decline in Q3 performance compared to past quarters.** Here's a detailed analysis:

1. **Revenue Decline**: BLNE's Q3 revenue was not disclosed, which makes it difficult to compare directly with past quarters. However, when comparing Q2 and Q4, we can infer that any changes in revenue would be reflected in these figures.
2. **Net Income and Diluted EPS**: Similarly, the net income and diluted EPS for Q3 were not provided, preventing a direct comparison with previous quarters. Again, by examining Q2 and Q4 data, we can assess any trends or changes.
3. **Trends in Q2 and Q4**:
- In Q2, BLNE's revenue was $0, net income was also $0, and the diluted EPS was $0.
- For Q4, no financial data was disclosed, including revenue, net income, and diluted EPS.
4. **Comparison with Estimates**:
- HP Inc. (HP) reported Q3 adjusted EPS of $0.83, which was slightly below the IBES estimate of $0.86.
- Concentrix reported Q3 adjusted EPS of $2.87, slightly below the IBES estimate of $2.93.
- Embecta reported Q3 revenue of $272.5 million, slightly above the IBES estimate of $267.4 million.
- Edgewell Personal Care reported Q3 sales of $647.8 million, slightly below the IBES estimate of $651.3 million.
- Quanex reported Q3 adjusted EPS of $0.73, which was slightly above the IBES estimate of $0.7.
5. **Insights from Estimates**:
- The estimates for Q3 revenue and earnings indicate that BLNE's performance might have been slightly below expectations, as evidenced by the comparisons with HP, Concentrix, Embecta, Edgewell Personal Care, and Quanex.
- Without the specific data for Q3, it is not possible to provide a definitive comparison. However, the lack of disclosed financial data for Q3 suggests that BLNE may not have performed as well as some of its peers during that quarter.

In conclusion, due to the unavailability of Q3 financial data, a direct comparison with past quarters cannot be made. However, by examining the estimates and trends from Q2 and Q4 data, it appears that BLNE's performance in Q3 might have been below average compared to its industry peers.